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Edited by Angel NebredaAbstract Claspin is involved in ATR-dependent activation of
Chk1 during DNA replication and in response to DNA damage.
We show that degradation of Claspin by the ubiquitin-proteo-
some pathway is regulated during the cell cycle. Claspin is stabi-
lized in S-phase but is abruptly degraded in mitosis and is absent
from early G1 cells in which the phosphorylation of Chk1 by
ATR is abrogated. In response to hydroxyurea, UV or aphidic-
olin, Claspin is phosphorylated in the Chk1-binding domain
and its protein levels are increased in an ATR-dependent manner.
Thus, the Chk1 pathway is regulated through both phosphoryla-
tion of Claspin and its controlled degradation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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DNA damage1. Introduction
Genomic integrity in eukaryotic cells is maintained by mech-
anisms that monitor DNA for damage or incomplete replica-
tion. Aberrant structures or stalled replication complexes
activate checkpoint pathways that delay cell cycle progression
and allow the damage to be repaired or replication to be com-
pleted [1]. Chk1 protein kinase is a central component of a con-
served checkpoint pathway activated by DNA damage or
replication stress that restrains progression through S-phase
and the G2/M transition [2]. Activation of Chk1 in response
to DNA damage or replication arrest induced by UV or
hydroxyurea involves ATR (ATM- and Rad3-related) kinase,
which phosphorylates human Chk1 at serines 317 and 345 [3,4].
Phosphorylation and activation of Chk1 by ATR in Xenopus
egg extracts requires Claspin, a protein identiﬁed by co-puriﬁ-
cation with Chk1 [5]. In human cells, Claspin is also thought
to be involved in Chk1 activation in response to DNA damage
or replication stress [6,7]. Claspin interacts with chromatin dur-
ing S-phase, indicating that it may act as a sensor of DNA rep-
lication [8,9]. The interaction of Claspin with Chk1 requires two
phosphorylation sites, threonine 916 and serine 945 in humans,
which form a tandem motif within the Chk1-binding domainAbbreviation: ATR, ATM- and Rad3-related
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doi:10.1016/j.febslet.2006.06.071(CKBD) [10,11]. Phosphorylation of these sites in Xenopus is
ATR-dependent but may not be catalysed directly by ATR [10].
We have previously shown that Claspin is cleaved in apopto-
tic human cells by caspase 7, which removes the Chk1-binding
domain and thereby prevents activation of Chk1 by ATR.
During these experiments, we found that Claspin was also lost
in a caspase-independent manner in HeLa cells treated with
TNFa and cycloheximide, an inhibitor of protein translation,
indicating a second pathway for the degradation of Claspin
[12]. Furthermore, the loss of Claspin in HeLa cells treated
with cycloheximide is inhibited by a proteosome inhibitor
[13]. Here, we report that caspase-independent degradation
of Claspin by the ubiquitin-proteosome pathway is regulated
during the cell cycle and in response to DNA replication arrest.
Our results indicate that the ATR-Chk1 pathway is controlled
during the somatic cell cycle by both the phosphorylation sta-
tus and abundance of Claspin.2. Methods
2.1. Tissue culture treatments
Human osteosarcoma U2OS cells were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium (GIBCO) supplemented with 10% fetal calf serum
(Biosera), 1% penicillin–streptomycin (GIBCO) and 1% L-glutamine
(GIBCO) at 37 C in 5% CO2. For protein turnover experiments, cells
were treated with 40 lg/ml cycloheximide (Sigma), 10 lM MG132
(Sigma) and 10 lM zVAD-fmk (z-Val-Ala-Asp-(OMe)-ﬂuoromethylk-
etone; BioMol). To induce DNA replication arrest or DNA damage,
cells were treated with 3 mM hydroxyurea (Sigma) or 3 lM aphidicolin
(Calbiochem) by adding directly to the growth medium or were treated
by removing the medium and exposing to 5 or 10 J/m2 UV in a Strat-
alinker 2400 (Stratagene).
2.2. Cell cycle analysis
To arrest cells at the G1/S boundary, a double thymidine block and
release experiment was performed where U2OS cells were treated for
16 h with 2 mM thymidine (Sigma), washed twice in warm PBS, re-
leased into fresh media for 8 h, treated for a further 16 h with 2 mM
thymidine, then released again into fresh media following two washes
in PBS. To synchronise cells in mitosis, U2OS cells were treated with
100 ng/ml nocodazole (Sigma) for 17 h, washed twice in warm PBS
then released into fresh media. Cells were lysed in SDS loading buﬀer
and protein concentrations determined using a protein assay kit (Bio-
Rad). Samples were analysed by SDS–PAGE and immunoblotting.
For FACS analysis, cells were pulsed with 30 lM BrdU for 15 min be-
fore collecting the ﬂoating cells and trypsinization of adherent cells fol-
lowed by centrifugation then ﬁxation in 70% ethanol. Cells were
treated with pepsin followed by mouse anti-BrdU antibodies and a-
mouse immunoglobulin conjugated to TRITC (Dako Cytomation) sec-
ondary antibody. Cells were then stained with propidium iodide and
analysed by ﬂow cytometric (FACS) analysis on a Becton Dickinsonblished by Elsevier B.V. All rights reserved.
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signed on the basis of the DNA content being 2 N, intermediate be-
tween 2 N and 4 N, and 4 N, respectively.
2.3. Transfections
For recovery of proteins labelled with His6-ubiquitin, U2OS cells
were transfected with 2 lg GFP-Claspin, His6-ubiquitin, empty GFP
vector or empty pcDNA vector. All transfections were made using
4 lg DNA in total using Superfect (Qiagen). Precipitation using nick-
el-agarose beads were performed as described previously (Xirodimas
et al., 2001). The His6-ubiquitin construct was a kind gift of Dimitris
Xirodimas, University of Dundee.
2.4. siRNA transfections
ATR expression was ablated using the SMARTpool (Dharmacon) of
four siRNA oligonucleotides (GAACAACACUGCUGGUUUGUU;
GGUCAGCUGUCUACUGUUAUU; GCAACUCGCCUAACAG-
AUAUU;ACUGAUGGCUGAUUAUUUAUU). The control duplex
was CGACCUGUAGCCCAAGAAAUU. Transfections were carried
out at 50 nM oligonucleotide using Lipofectamine 2000 (Invitrogen).
2.5. Antibodies
The rabbit polyclonal a-pT916 Claspin antibody was raised against
the peptide MDELLDLCpTGFTSQA, where pT is phosphothreonine,
coupled at its amino terminal with KHL for immunisation in rabbits.
The crude serum was subjected to two rounds of negative selective
against the corresponding non-phosphorylated peptide before the ﬁnal
positive selection against the phosphorylated peptide. Commercial
antibodies used were: rabbit a-Claspin (BL73; Bethyl Laboratories);
a-ATR (FRP1; N-19), mouse monoclonal a-Chk1 (G-4), rabbit a-cy-Fig. 1. Claspin is turned over in non-apoptotic cells in a proteasome-depend
presence of cycloheximide in a caspase-independent manner that is dependent
the absence or presence of the caspase inhibitor zVAD-fmk (10 lM) or the pro
shown by immunoblotting. (B) Claspin is ubiquitylated. U2OS were transfect
as indicated for 40 h. Ubiquitylated proteins were precipitated on nickel-agaclin B1 (H-433) (all Santa Cruz Biotechnology); rabbit a-Chk1 phos-
phorylated on Ser345 (Cell Signalling Technology); rabbit a-PARP
(MCA1522G; Serotec); rabbit a-actin (A-2066; Sigma); rabbit a-phos-
phohistone H3 Ser10 (06-570; Upstate); mouse a-cyclin A and a-BrdU
(both BD Biosciences). Secondary horseradish peroxidase-conjugated
antibodies for immunoblotting were a-mouse immunoglobulin, a-rab-
bit immunoglobulin (both BioRad) or a-goat immunoglobulin (Santa
Cruz Biotechnology). For immunoﬂuorescence a-rabbit immunoglob-
ulin conjugated to TRITC (Dako Cytomation) and a-mouse immuno-
globulin conjugated to FITC (F-9137; Sigma).
2.6. Immunoﬂuoresence
Cells were grown on coverslips and were left untreated or pulsed
with 30 lMBrdU for 15 min before being ﬁxed with 3% paraformalde-
hyde for 15 min then permeabilized with 0.5% Trition X-100 for 7 min.
Slides were incubated with primary antibodies for 3 h at room temper-
ature then FITC-conjugated anti mouse and TRITC-conjugated anti
rabbit secondary antibodies for 1 h. All antibodies were diluted in
0.1% non-fat milk. Cells were counterstained with 4-6-diamidino-2-
phenylindole (DAPI) dye for 2 min. For quantiﬁcation of results, at
least 800 cells were analysed.3. Results
3.1. Degradation of Claspin by the proteasome is caspase-
independent and involves ubiquitylation of Claspin
Claspin was rapidly lost with a half-life of under 2 h in asyn-
chronous U2OS cells treated with cycloheximide (Fig 1A),ent manner and is ubiquitylated. (A) Claspin is rapidly degraded in the
on the proteosome. U2OS were treated with 40 lg/ml cycloheximide in
teosome inhibitor MG132 (10 lM). Samples were analysed at the times
ed with His6-ubiquitin and/or GFP-Claspin, and/or empty GFP vector
rose beads, then analysed by immunoblotting.
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caspase-mediated proteolysis that might have been induced by
cycloheximide, since the disappearance of Claspin was not af-
fected by the caspase inhibitor zVAD-FMK and no coincident
caspase-dependent cleavage of poly(ADP-ribose) polymerase
(PARP) was observed. By contrast, loss of Claspin was pre-
vented by the proteasome inhibitor MG132, which alone
caused an increase in the level of Claspin, conﬁrming that
the protein is turned over in a proteasome-dependent manner.
When cells were co-transfected with GFP-Claspin and His6-
ubiquitin, GFP-tagged and endogenous Claspin were both
recovered as ubiquitylated proteins (Fig 1B), demonstrating
that Claspin is directly modiﬁed. Thus, Claspin is ubiquity-
lated in order to mark the protein for degradation by the pro-
teasome-dependent pathway.Fig. 2. Cell cycle regulation of Claspin. U2OS cells were synchronised
(A) at the G1–S boundary using a double thymidine block or (B) in
mitosis with nocodazole. Samples were taken at selected time points
following release from the arrest and analysed by immunoblotting
using the antibodies indicated, including histone H3 phosphorylated at
Ser10 (pHH3). Samples from asynchronous cells (As) are also shown.
Cell cycle analysis of cells taken at the same times by FACS is shown
below (see Supplementary Figs. 1 and 2 for data).3.2. Claspin is rapidly degraded at a late stage of mitosis
Previous experiments have shown that Claspin, like Chk1, is
down regulated when T24 bladder carcinoma cells exit the cell
cycle due to conﬂuence and is resynthesised when the cells re-
enter the cell cycle, reaching a peak at G1/S [6,7]. To study the
level of Claspin more precisely within the cell cycle, U2OS cells
were synchronised at the G1–S boundary using a double thy-
midine block, then released and followed through the cell cycle
by ﬂow cytometric (FACS) analysis (Supplementary ﬁg 1).
Claspin from asynchronous cells migrated on SDS-PAGE as
several bands that correspond to phosphorylated forms
(Fig. 2A) [6,7]. In thymidine-blocked cells, there was a strong
increase in the amount of Claspin, which was hypophosphory-
lated. As cells entered S-phase, 2–6 h after release from the
block, Claspin was apparently phosphorylated progressively
at multiple sites. As cells ﬁnished S-phase and entered G2 after
8 h, Claspin levels declined slightly and the protein became
hypophosphorylated again. Claspin persisted during mitosis,
marked by histone H3 phosphorylation at Ser10 (10 h), but
was not present in G1 when cyclin A was also absent (14 h).
Claspin was restored as cells entered a second S-phase and be-
came less synchronised after 24 h. In contrast to Claspin, the
level of Chk1 remained constant throughout the cell cycle.
Therefore, although both Claspin and Chk1 are downregu-
lated on exit from the cell cycle [6], only Claspin levels are reg-
ulated during progression through the cell cycle.
To study the timing of Claspin loss, U2OS cells were syn-
chronised in mitosis with nocodazole and released into G1 fol-
lowed by FACS analysis (Supplementary ﬁg 2). Claspin levels
were lower in nocodazole-treated cells than in asynchronous
cells, suggesting that some Claspin is degraded during mitotic
arrest, like cyclin A (Fig. 2B). The remaining Claspin, which
was hypophosphorylated, was further reduced 1–1.5 h after
release from the arrest, like cyclin B1. By 2 h, when the
majority of cells were in G1, Claspin was almost undetectable.
Claspin reappeared after 8 h as cells entered S-phase and was
present as multiple upshifted forms indicating phosphoryla-
tion at several sites. As expected, Chk1 levels remained con-
stant throughout mitosis and G1 (Fig. 2B). Similar results
were obtained using HeLa cells (data not shown). We infer
that degradation of some Claspin starts in mid-mitosis, like
cyclin A, and the rest is lost towards the end of mitosis after
cyclin A has been degraded and at about the same time as cy-
clin B1 is degraded, which corresponds to anaphase/telophase
[14].3.3. G1 cells lacking Claspin are unable to induce a checkpoint
response to UV
To conﬁrm the cell cycle regulation of Claspin at the level of
individual cells, we performed immunoﬂuorescence with ﬁxed
U2OS cells. Cyclin A was used as a marker of S-, G2- and pro-
phase cells (Fig. 3A), while S-phase cells were distinguished by
incorporation of BrdU into newly synthesised DNA (Fig. 3B).
All cells with cyclin A also contained Claspin within their nu-
clei, while a small number of cells that contained Claspin had
undetectable cyclin A. The latter included mitotic cells in
which Claspin was detectable, cyclin A being degraded after
prophase [14], but also some cells with interphase nuclei that
were probably in late G1/early S-phase (data not shown). All
S-phase cells that incorporated BrdU were also positive for
Claspin within their nuclei (Fig. 3B). Of the cells that did
not incorporate BrdU, some were positive for Claspin (G2
cells), whereas Claspin was absent in others (G1 cells)
(Fig. 3B). Together, these data demonstrate that Claspin is ab-
sent in early G1 cells, reappears in late G1, and persists through
S and G2 until the end of the next mitosis.
Recently it has been shown that G1 cells lack the ability to
activate the ATR-Chk1 pathway in response to ionizing radi-
ation [15,16]. We found that when U2OS cells were treated
Fig. 3. Claspin is absent in G1 cells in which Chk1 phosphorylation is abrogated. (A) Cells which lack cyclin A also lack Claspin.
Immunoﬂuorescence of U2OS cells was performed with a-Claspin and a-cyclin A antibodies. DNA was stained with DAPI. The percentage of cells
expressing Claspin and cyclin A is shown below. (B) S-phase cells contain Claspin. Expression of Claspin and incorporation of BrdU was detected by
speciﬁc antibodies. (C) G1 cells lacking Claspin are unable to phosphorylate Chk1 at Ser345. U2OS cells were synchronised using nocodazole, then
mitotic cells were washed oﬀ and reseeded in fresh media. 2 h post release, cells were irradiated with UV, harvested 1.5 h later and analysed by
immunoblotting.
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phorylation of Claspin at Thr916, conﬁrming that this site is
phosphorylated in human cells, and increased Chk1 phosphor-
ylation at Ser345, as expected (Fig. 3C). By contrast, cells syn-
chronised in early G1 by a nocodazole block and release
protocol, completely lacked Claspin and were unable to induce
phosphorylation of Chk1 above basal levels. This indicates
that the inability to activate Chk1 in early G1 cells is likely
to be due in part to the absence of Claspin, although other fac-
tors may also play a role.3.4. ATR-dependent control of Claspin phosphorylation and
stabilisation
When U2OS cells were incubated for prolonged periods
(16–24 h) with aphidicolin or hydroxyurea, the total level of
Claspin was strongly increased, particularly by aphidicolin.
Phosphorylation of Claspin and Chk1 at Thr916 and Ser345,
respectively, was also induced, as expected (Fig. 4A). To test
if the increase in Claspin was due to inhibition of its degrada-
tion, we compared the rate of degradation of Claspin in asyn-
chronous cells and aphidicolin-treated cells. Aphidicolin
Fig. 4. Regulation of Claspin phosphorylation and stability. (A) DNA replication arrest increases the amount of Claspin in cells. U2OS cells were
treated with 3 lM aphidicolin or 3 mM hydroxyurea for 16 or 24 h. (B) DNA replication arrest inhibits the degradation of Claspin. U2OS cells were
incubated for 16 h with or without 3 lM aphidicolin, one sample was taken, then 40 lg/ml cycloheximide was added and further samples taken at 2, 4
and 6 h. (C and D) Claspin phosphorylation at Thr916 and increased levels of the protein in response to DNA damage or replication arrest are ATR
dependent. U2OS cells were transfected with ATR siRNA and left 72 h before being treated with 5 J/m2 UV and incubated for 2 h, or 3 mM
hydroxyurea or 3 lM aphidicolin for 2 h. In each experiment, samples were analysed by immunoblotting using the indicated antibodies. In (B) both
long and short exposure of the a-Claspin immunoblot are shown to allow comparison of the turnover rate of the protein in both conditions.
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and clearly inhibited the rate of degradation of the protein fol-
lowing cycloheximide addition, increasing the half-life of the
protein from less than 2 h to about 4 h (Fig. 4B). Thus, stabil-
isation of Claspin is part of the checkpoint response to DNA
replication arrest.
To determine the role of ATR in the control of Claspin lev-
els, as well as its phosphorylation at Th916, we ablated the
expression of ATR by siRNA. Loss of ATR blocked the phos-
phorylation of Claspin at Thr916 in response to aphidicolin
(Fig. 4C), UV radiation or hydroxyurea (HU) (Fig. 4D). As
expected, loss of ATR also prevented the phosphorylation of
Chk1 at Ser345, which is associated with Chk1 activation.
The increased level of Claspin induced by aphidicolin, UV or
HU was also prevented by ATR ablation, showing that
ATR is required for Claspin stabilisation in response to these
treatments.4. Discussion
Claspin plays an essential role in the ATR-dependent phos-
phorylation and activation of Chk1 during DNA replication
arrest in Xenopus egg extracts. In this embryonic system, which
oscillates between S-phase and mitosis, the protein is present
constitutively [5]. Our results show that the abundance of
human Claspin is highly regulated during the somatic cell cyclethrough changes in the rate of degradation via the ubiquitin-
proteosome pathway.
Claspin is dramatically lost in late mitosis and is absent
from early G1 cells, which are unable to activate Chk1. One
possible functional consequence may be that cells can establish
the ﬁrst replication complexes at G1/S without initiating a
checkpoint response. At the transition into S-phase, Claspin
could then be recruited to sites of replication initiation where
it would allow the activation of Chk1 by ATR and the repres-
sion of secondary replication complexes as part of intra-S-
phase checkpoint controls [17,18]. An alternative possibility
is that Claspin has a positive role in DNA replication so that
its absence in G1 cells prevents premature S-phase. Interest-
ingly, Claspin appears to be phosphorylated at multiple sites
during S-phase that may regulate its function or stability.
The presence of Claspin in G2 and early mitotic cells suggests
a continuing role in checkpoint control after DNA replica-
tion, and may allow a Chk1 response to be mounted even in
mitosis.
We show that the ATR-dependent response to DNA dam-
age or replication arrest involves both phosphorylation of Cla-
spin at Thr916, which creates a Chk1-binding motif [10,11],
and increased levels of Claspin through stabilisation of the
protein. Further investigation will be aimed at determining
how Claspin degradation is inhibited during DNA replication
arrest and suddenly activated towards the end of mitosis. The
potential role of phosphorylation in controlling the stability of
L.N. Bennett, P.R. Clarke / FEBS Letters 580 (2006) 4176–4181 4181Claspin and the identity of the enzymes controlling its ubiqui-
tylation will be of particular interest.
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